Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line

Journal of Chemotherapy

Volumn 24, Issue 1, 2012, Pages 48-55

  Manceau, Sandra ^a,b   Giraud, Carole ^a,b   Declèves, Xavier ^c   Batteux, Frédéric ^a   Chéreau, Christiane ^a   Chouzenoux, Sandrine ^a   Scherrmann, Jean Michel ^b   Weill, Bernard ^a   Perrot, Jean Yves ^b   Tréluyer, Jean Marc ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Assistance Publique Hôpitaux de Paris ^*  (France)

^c INSERM   (France)

Author keywords

ABC transporter; ABCB1; CCRF CEM cells; Dexamethasone; Lymphocyte; Nuclear receptor

Indexed keywords

CELL NUCLEUS RECEPTOR; DEXAMETHASONE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INCUBATION TIME; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ATP-BINDING CASSETTE TRANSPORTERS; DEXAMETHASONE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84866242423     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1120009X12Z.00000000010     Document Type: Article

References (52)

1. Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet. 2007;46(6):449-70.
2. Giraud C, Decleves X, Perrot J, Manceau S, Pannier E, Firtion G, et al. High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life. Clin Pharmacol Ther. 2009;85(3):289-95.
3. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;80(11):2735-9.
4. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473-8.
5. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004;21(7):1284-93.
6. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003;22(47):7496-511.
7. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother. 2004;54(6):982-90.
8. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS. 2001;15(6):675-81.
9. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006;25(4):231-59.
10. Richaud-Patin Y, Vega-Boada F, Vidaller A, Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed Pharmacother. 2004;58(5):320-4.
11. Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol. 1996;35(5):430-5.
12. Hirano T, Onda K, Toma T, Miyaoka M, Moriyasu F, Oka K. MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration. J Clin Pharmacol. 2004;44(5):481-6.
13. Tanaka S, Masuda M, Nakajima K, Ido N, Ohtsuka T, Nishida M, et al. P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: clinical implications and influence of glucocorticoid administration. Int Immunopharmacol. 2009;9(3):284-90.
14. Seree E, Villard PH, Hever A, Guigal N, Puyoou F, Charvet B, et al. Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun. 1998;252(2):392-5.
15. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581-7.
16. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol. 2008;153(4):805-19.
17. Nishimura M, Koeda A, Morikawa H, Satoh T, Narimatsu S, Naito S. Comparison of inducibility of multidrug resistance (MDR)1, multidrug resistance-associated protein (MRP)1, and MRP2 mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes. Biol Pharm Bull. 2008;31(11):2068-72.
18. Nishimura M, Koeda A, Suzuki E, Kawano Y, Nakayama M, Satoh T, et al. Regulation of mRNA expression of MDR1, MRP1, MRP2 and MRP3 by prototypical microsomal enzyme inducers in primary cultures of human and rat hepatocytes. Drug Metab Pharmacokinet. 2006;21(4):297-307.
19. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol. 2000;58(2):361-72.
20. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem. 2001;268(24):6346-58.
21. Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M, et al. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos. 2003;31(5): 620-30.
22. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet. 2003;42(15):1331-57.
23. Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem. 2005;386(6): 503-13.
24. Pavek P, Cerveny L, Svecova L, Brysch M, Libra A, Vrzal R, et al. Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta. 2007;28(10):1004-11.
25. Pulaski L, Kania K, Ratajewski M, Uchiumi T, Kuwano M, Bartosz G. Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005;96(3-4):229-34.
26. van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis. 2004;63(2):131-7.
27. Matarrese P, Testa U, Cauda R, Vella S, Gambardella L, Malorni W. Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. Biochem J. 2001;355(Pt 3):587-95.
28. Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4z T lymphoblastoid CEM cell line. Chemotherapy. 2003;49(1/2):8-16.
29. Oerlemans R, van der Heijden J, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, et al. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistanceassociated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum. 2006;54(2):557-68.
30. Owen A, Hartkoorn RC, Khoo S, Back D. Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines. AIDS. 2003;17(15):2276-8.
31. Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res. 2008;32(5):799-809.
32. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol. 2008; 153 (Suppl 2):S1-209.
33. Mark PJ, Waddell BJ. P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells. Endocrinology. 2006;147(11):5147-52.
34. Ambroziak K, Kuteykin-Teplyakov K, Luna-Tortos C, Al-Falah M, Fedrowitz M, Loscher W. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur J Pharmacol. 2010;628(1-3):57-66.
35. McClean S, Hosking LK, Hill BT. Expression of P-glycoprotein-mediated drug resistance in CHO cells surviving a single X-ray dose of 30 Gy. Int J Radiat Biol. 1993;63(6):765-73.
36. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem. 2003; 278(12):10344-52.
37. Gomez A, Garcia-Morales P, Carrato A, Castro-Galache MD, Soto JL, Carrasco-Garcia E, et al. Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res. 2007;5(6):641-53.
38. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996;49(2):311-8.
39. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003;63(5):1094-103.
40. Pedersen KB, Vedeckis WV. Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines. Biochemistry. 2003;42(37):10978-90.
41. Bachmann PS, Gorman R, Papa RA, Bardell JE, Ford J, Kees UR, et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res. 2007;67(9):4482-90.
42. Eisen LP, Elsasser MS, Harmon JM. Positive regulation of the glucocorticoid receptor in human T-cells sensitive to the cyto-lytic effects of glucocorticoids. J Biol Chem. 1988;263(24):12044-8.
43. Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, et al. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol Pharmacol. 2008;73(2):451-60.
44. Gomi M, Moriwaki K, Katagiri S, Kurata Y, Thompson EB. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res. 1990;50(6):1873-8.
45. Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol. 2000;58(6):1441-50.
46. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002;277(4):2908-15.
47. Huss JM, Kasper CB. Two-stage glucocorticoid induction of CYP3A23 through both the glucocorticoid and pregnane X receptors. Mol Pharmacol. 2000;58(1):48-57.
48. Giraud C, Manceau S, Treluyer JM. ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin Drug Metab Toxicol. 2010;6(5):571-89.
49. Giraud C, Manceau S, Decleves X, Goffinet F, Morini JP, Chappuy H, et al. Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes. J Clin Pharmacol. 2010;50(2):226-30.
50. Manceau S, Giraud C, Decleves X, Batteux F, Chouzenoux S, Tang R, et al. Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes. Int J Pharm. 2010;395(1/2):98-103.
51. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, et al. Multidrug resistance-associated protein 1expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia. 2007;21(3):427-38.
52. Ruiz-Soto R, Richaud-Patin Y, Lopez-Karpovitch X, Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp Hematol. 2003;31(6): 483-7.